BTIG analyst Mark Massaro has reiterated their neutral stance on TKNO stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mark Massaro has given his Hold rating due to a combination of factors, including Teknova’s modest top-line beat in Q4 and its conservative outlook for 2026. While the company is seeing encouraging momentum in areas like liquid biopsy, life science tools, and next-generation sequencing, its initial 2026 revenue guidance is slightly below consensus and implies only mid-single-digit growth, which tempers the near-term upside case.
At the same time, Teknova is increasing investments in its commercial organization and marketing, delaying the timeline to adjusted EBITDA breakeven, which adds execution risk. Coupled with ongoing macro and end-market headwinds in the life sciences sector and a valuation that stands at a premium to comparable small-cap tools peers, Massaro concludes that the shares are appropriately priced at current levels, supporting a Hold rather than a more positive rating.
In another report released today, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $2.00 price target.